TICKERNERD
Menu
COCHCOCHHealthcare · Medical Devices

COCH Stock Forecast: Envoy Medical, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.74
+4.25% on the day

The 2 Wall Street analysts covering Envoy Medical, Inc. hold a median 12-month price target of $2 — +170.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$57.1M
Ticker Nerd rank
34 / 100
Median analyst target
$2.00
Analysts covering
2
Revenue$51K−34.6% y/y
Operating income−$5.6M
Net income−$6.0M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
−3.9%
YTD
+12.0%
1Y
−44.3%
From 52W high
−53.4%
From 52W low
+89.8%
$0.39
$1.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COCH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Envoy Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
81
Accruals
74
Issuance
61
Growth
57
Revisions
45
Volatility
37
Momentum
32
Value
14
Quality
3

Size (81): Smaller than most of the companies we track.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COCH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COCH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Oct 25Jan 26Apr 26Jul 26COCHHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $2.00Median $2.00High $2.00

The green dot is the last close — the median target sits +170.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026HC Wainwright & Co.MaintainsBuy$2.50 → $2.00
27 July 2026LUCID CAPITAL MARKETSInitiatesBuy—
27 July 2026LUCID CAPITAL MARKETSInitiatesBuy$2.00
15 July 2026HC Wainwright & Co.ReiteratesBuy$2.50
15 July 2026HC Wainwright & Co.ReiteratesBuy—
31 Mar 2026HC Wainwright & Co.InitiatesBuy$2.50
31 Mar 2026HC Wainwright & Co.InitiatesBuy—
27 May 2025Ascendiant CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
6 Dec 2024Ascendiant CapitalMaintainsBuy—
14 Oct 2024Brookline CapitalInitiatesBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
24 June 2024Ascendiant CapitalInitiatesBuy—
3 Apr 2024Lake StreetMaintainsBuy—
21 Dec 2023Northland Capital MarketsInitiatesOutperform—
28 Nov 2023Lake StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COCH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COCH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Envoy Medical, Inc. returned −44.3% against +17.5% for the S&P 500, dividends included.

COCH vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26COCHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COCH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Envoy Medical, Inc. (COCH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 80% of US stocks

Price / sales
276.0×

Cheaper than 3% of US stocks

Price / book
15.4×

Cheaper than 6% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−34.6%

Higher than 8% of US stocks

Earnings growth (YoY)
−34.6%

Higher than 14% of US stocks

Gross margin
−445.1%

Higher than 1% of US stocks

Operating margin
−10919.6%

Higher than 2% of US stocks

Net margin
−262.7%

Higher than 1% of US stocks

Returns & dividend
Return on equity
243.6%

Higher than 99% of US stocks

Return on assets
−86.5%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Envoy Medical, Inc. (COCH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Envoy Medical, Inc. has a market value of $57.1M and an enterprise value of $38.3M.

  • Revenue in the twelve months to 30 June 2026: $207K. The latest quarter shrank 34.6% year on year.

  • Net income over the same four quarters: −$23.4M, a −11304.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$21.7M.

  • Envoy Medical, Inc. spent $1K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 77.2M.

  • Trailing P/E: −0.6×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Envoy Medical, Inc. employs 43 people — $5K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

COCH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
COCHEnvoy Medical, Inc.$57.1M
34
NNOXNano-X Imaging Ltd.$56.9M
19
OMOutset Medical, Inc.$58.7M
29
RPIDRapid Micro Biosystems, Inc.$61.3M
28
SRTSSensus Healthcare, Inc.$51.8M
51
MYOMyomo, Inc.$51.5M
53
MDAISpectral AI, Inc.$49.1M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Envoy Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COCH news & analysis

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Newsfile Corp · 2 Sept 2026positive

Envoy Medical announced that CEO Brent Lucas will present at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. The presentation highlights the company's participation in a major investor event.

Why it matters — The company's CEO presenting at a major investment conference provides Envoy Medical with visibility and an opportunity to engage with investors in the investment community.

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 10 Aug 2026positive

Envoy Medical reported a quarterly loss of $0.07 per share, narrower than the Zacks Consensus Estimate of a $0.09 loss and an improvement from the $0.32 per-share loss a year earlier.

Why it matters — The narrower-than-expected loss and the year-over-year improvement provide COCH watchers with a clear data point on the company's most recent quarterly performance.

Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

Newsfile Corp · 10 Aug 2026positive

Envoy Medical reported second quarter 2026 financial results and provided a business update. Subsequent to the quarter's end, the company submitted the first module of its Modular PMA application to the FDA, and reported positive 12-month Stage 1 data showing continued improvement in speech perception for its fully implanted cochlear implant.

Why it matters — These regulatory and clinical milestones signal progress toward bringing Envoy Medical's fully implanted cochlear implant to market.

FAQ

Frequently asked questions about COCH stock

What is the COCH stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Envoy Medical, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COCH stock a buy right now?

Of the 2 analysts covering Envoy Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envoy Medical, Inc. 34 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COCH?

As at 11 Sept 2026, Envoy Medical, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).

Will COCH stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +170.2% from the last close, and Ticker Nerd's factor model ranks Envoy Medical, Inc. 34 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COCH stock forecast for 2030?

No analyst covering Envoy Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has COCH stock performed over the past year?

Envoy Medical, Inc. returned -44.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Envoy Medical, Inc. do?

Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components.

What is the latest news on COCH?

The most recent item we track (Newsfile Corp, 2 Sept 2026): "Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th". Envoy Medical announced that CEO Brent Lucas will present at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. The presentation highlights the company's participation in a major investor event.

Company

About Envoy Medical, Inc.

Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components. Envoy Medical also has an investigational cochlear implant program under development, reflecting its broader role in the hearing device market. Based in White Bear Lake, Minnesota, the company operates in the healthcare and medical devices space and serves patients and providers seeking alternatives to traditional hearing aids and other hearing technologies. Its business is concentrated in the hearing segment, where it aims to improve usability, access, and quality of life through implantable solutions.

CEO Mr. Brent T. Lucas Esq. · 43 employees · United States · https://www.envoymedical.com